27th March 2020
Prof Schett from University of Erlangen-Nuremberg.
Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Prof Schett discusses how JAK inhibitors can increase bone formation by stimulating osteoblasts.
23rd March 2020
Professor Iain McInnes presents the Discussion Rheum Podcast. In this edition he focuses on JAK Inhibition on bone homeostasis and bone healing.
11th March 2020
Professor Iain McInnes explores what motivated him to pursue rheumatology, the inception of JAK inhibitors during his time at the National Institutes of Health, and his current role as President of EULAR.
27th February 2020
Professor Peter Nash Interviews Dr Orsolini from the University of Verona about differences in bone homeostasis between RA and PsA and the potential of JAK inhibitors to halt bone erosion, independent of their effects on inflammation.
21st February 2020
Professor Iain McInnes presents the Discussion Rheum Podcast. In this edition he focuses on upadacitinib JAK 1 selectivity in comparison to tofacitinib, and filgotinib’s effect on biomarkers implicated in RA.
07th February 2020
Professor Anca Catrina, explores the role of antibodies in the pathogenesis of RA and their contribution to; pain, bone-loss, and fibroblast activation.
29th January 2020
Professor Peter Nash interviews Professor Vibeke Strand from Stanford University about improvements in patient-reported outcomes with upadacitinib. Click below to access the summary slides.
Effects of Upadacitinib on Patient-Reported Outcomes: Results from SELECT-BEYOND and SELECT-NEXT.
22nd January 2020
Patient-reported Outcomes with Tofacitinib from the 24-month Phase 3 ORAL Scan study
Safety, Tolerability and Pharmacokinetics of the Novel BTK Inhibitor Evobrutinib
10th January 2020
Professor Winthrop identifies Herpes Zoster (HZ) as large unmet need in autoimmune inflammatory disease, discussing the impact concomitant treatments have on HZ risk and the potential of the new sub-unit HZ vaccine compared with the live vaccines currently in routine use.
23rd December 2019
Professor McInnes presents the Highlights of 2019.
We can be optimistic that clinical practice for inflammatory arthritis will continue to improve, with promising long-term safety data supporting the use of established JAK inhibitors; tofacitinib and baricitinib, in addition to exciting phase III clinical data for filgotinib and newly approved upadacitinib.
23rd December 2019
Safety of Baricitinib in East Asian Patients With Moderate to Severe Active Rheumatoid Arthritis
Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis
28th November 2019
A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis...
Comparative Efficacy and Safety of Peficitinib 25, 50, 100, and 150 mg in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta?Analysis of Randomized Controlled Trials...
24th November 2019
In this edition of Congress Author Podcasts, recorded at ACR 2019, the latest data from the FINCH studies are presented by Professors Taylor, Westhovens and Winthrop, in addition to filgotinib safety data from a phase 2 Psoriatic Arthritis trial, presented by Professor Coates.
Download the Posters Here
23rd November 2019
In this edition of Congress Author Podcasts, recorded at ACR 2019,
real-world tofacitinib safety data is presented by Professor Joel Kremer and the impact of baricitinib and tofacitinib on pain is analysed by Professors Peter Taylor and Maxime Dougados.
Download the Posters Here
22nd November 2019
Introducing Congress Author Podcasts, a new podcast series where authors review their congress posters and presentations on cytokine signalling and JAK inhibitors. The first edition, recorded at ACR 2019 in Atlanta, focuses on upadacitinib.
Download the Posters Here
19th November 2019
Professor Kevin Winthrop and Professor Leonard Calabrese present the key abstracts presented at this year's ACR conference in Atlanta.
31st October 2019
Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function
Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib
26th September 2019
Comparison of Baricitinib, Upadacitinib, and Tofacitinib Mediated Regulation of Cytokine Signalling in Human Leukocyte Subpopulations...
Outcomes of Dose Reduction, Withdrawal, and Restart of Tofacitinib in Patients with Rheumatoid Arthritis: A Prospective Observational Study...
26th September 2019
Professor Iain McInnes joined by Professor Johannes Bijlsma, discusses the changes required to educate the next generation of rheumatologists, highlighting the benefits of online educational courses and the importance of quality amid a plethora of information.
19th September 2019
Safety and Effectiveness of Upadacitinib or Adalimumab Plus Methotrexate in Patients with Rheumatoid Arthritis Over 48 Weeks with Switch to Alternate Therapy in Patients with Insufficient Response....
Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase 3, Double-Blind, Randomized Controlled Trial....
09th September 2019
27th August 2019
Safety and Effectiveness of Upadacitinib or Adalimumab Plus Methotrexate in Patients with Rheumatoid Arthritis Over 48 Weeks...
Efficacy and Safety of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate...
14th August 2019
29th July 2019
Clinical Outcomes in Patients Switched from ADA to BARI due to Non-response and/or Study Design: Phase III in Patients with Rheumatoid Arthritis...
Live Zoster Vaccine in Patients with Rheumatoid Arthritis Treated with Tofacitinib with or without Methotrexate, or Adalimumab with Methotrexate...
27th June 2019
Upadacitinib as Monotherapy in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate (SELECT-MONOTHERAPY)...
Impact of Janus Kinase Inhibitors on Risk of Cardiovascular Events in Patients with Rheumatoid Arthritis...
30th May 2019
23rd May 2019
Evaluation of Pneumococcal and Tetanus Vaccine Responses in Patients with Rheumatoid Arthritis Receiving Baricitinib: Results from a Long-Term Extension Trial Substudy...
Safety and Efficacy of Tofacitinib For Up to 9.5-Years in The Treatment of Rheumatoid Arthritis: Final Results of a Global, Open-Label, Long-Term Extension Study...
10th May 2019
25th April 2019
Efficacy and Safety Data Based on Historical or Pre-Existing Conditions at Baseline for Patients with Active Rheumatoid Arthritis Who Were Treated with Baricitinib...
Tuberculosis, Hepatitis B and Herpes Zoster in Tofacitinib-Treated Patients with Rheumatoid Arthritis...
23rd April 2019
10th April 2019
22nd March 2019
Baricitinib Induces LDL-C and HDL-C Increases in Rheumatoid Arthritis: A Meta-Analysis of Randomized Controlled Trials...
Network Meta-Analysis of Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients...
13th March 2019
04th March 2019
Cardiovascular Safety During Treatment with Baricitinib in Rheumatoid Arthritis...
Tofacitinib in Combination with Methotrexate in Patients with Rheumatoid Arthritis: Clinical Efficacy, Radiographic and Safety Outcomes from the 24-Month Phase 3 ORAL Scan Study...
28th January 2019
Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated Analysis...
A Pooled analysis of the Safety of Tofacitinib as Monotherapy or in Combination with Background Conventional Synthetic Disease-Modifying Antirheumatic Drugs in a Phase 3 Rheumatoid Arthritis Population...
11th January 2019
Influence of Age and Renal Impairment on the Steady State Pharmacokinetics of Filgotinib, a Selective JAK1 Inhibitor...
Evaluation of the Short-, Mid-, and Long-term Effects of Tofacitinib on Lymphocytes in Patients with Rheumatoid Arthritis...
07th January 2019
04th December 2018
Herpes zoster in Tofacitinib: Risk is Further Increased with Glucocorticoids but not Methotrexate...
30th November 2018
Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids...
Herpes zoster in Tofacitinib: Risk is Further Increased with Glucocorticoids but not Methotrexate...
16th November 2018
- Dr Alan Kivitz discussing his SYK inhibitor data: 00:00-2:09
- Dr Rebecca Kunder talks about the FIL safety study: 2:10-8:12
- Dr Heather Litman describes real-world immunomodulator data: 8:13-10:55
- Professor Roy Fleischmann analyses BARI rescue data: 10.56-15.02
- Dr Lucia Domínguez-Casas reviewes respiratory infection factors: 15.03-17:00
- Professor Peter Taylor with Dr Amer Mirza discuss JAK inhibitor biomarkers: 17:01-18:57
29th October 2018
Dose Reduction of Baricitinib in Patients with Rheumatoid Arthritis Achieving Sustained Disease Control: Results of a Prospective Study...
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment...
09th October 2018
Sustained Response Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab...
Lipid Profile and Effect of Statin Treatment in Pooled Phase II and Phase III Baricitinib Studies...
03rd October 2018
28th August 2018
Tocilizumab Discontinuation After Attaining Remission in Patients with Rheumatoid Arthritis who were Treated with Tocilizumab Alone or in Combination with Methotrexate...
Two Years of Sarilumab in Patients with Rheumatoid Arthritis and an Inadequate Response to MTX...
24th August 2018
25th July 2018
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (SELECT-NEXT)...
Safety and Efficacy of Upadacitinib in Patients with Active Rheumatoid Arthritis Refractory To Biologic Disease-Modifying Anti-Rheumatic Drugs (SELECT-BEYOND)...
30th June 2018
Long-term Radiographic and Patient-reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib...
Effects of Baricitinib on Radiographic Progression of Structural Joint Damage at 1 year...
30th May 2018
23rd May 2018
Tofacitinib in Rhuematoid Arthritis: Lack of Early Change in Disease Activity Predicts...
Evaluation of Disease Activity in Patients with Rheumatoid Arthritis Treated with Tofacitinib by RAPID3..
27th April 2018
Effectiveness and Safety of Tofacitinib in Rheumatoid Arthritis: a Cohort Study...
Effect of Filgotinib, a Selective JAK1 Inhibitor, with or without Methotrexate in Patients with Rheumatoid Arthritis: Patient-Reported Outcomes..
29th March 2018
29th March 2018
Response to Baricitinib based on Prior Biologic Use in Patients with Refractory Arthritis...
Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis...
Worldwide, 3-year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis...
28th February 2018
28th February 2018
Tofacitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Chinese Patients with Rheumatoid Arthritis: Patient-reported Outcomes...
Radiographic Joint Damage in Early Rheumatoid Arthritis Patients: Comparing Tocilizumab- and Methotrexate-based...
02nd February 2018
29th January 2018
Patient-Reported Outcomes in Newly Diagnosed Early Rheumatoid Arthritis Patients Treated to Target with a Tocilizumab- or Methotrexate-based Strategy...
Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including...
21st December 2017
Long-term Effectiveness of Tocilizumab in Patients with Rheumatoid Arthritis, Stratified by Number of Previous Treatment Failures with Biologic Agents: Results from the German RABBIT Cohort...
Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naive and Experienced Patients...
30th November 2017
Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA...
Safety and Efficacy of Baricitinib in Elderly Patients with Rheumatoid Arthritis...
30th October 2017
Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program...
Patient-reported Outcomes of Baricitinib in Patients with Rheumatoid Arthritis and...
21st September 2017
Patient-reported Outcomes from a Phase 3 Study of Baricitinib versus...
Herpes Zoster and Tofacitinib Therapy in Patients with Rheumatoid Arthritis...
21st August 2017
Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor...
Analysis of Non-melanoma Skin Cancer across the Tofacitinib ...
25th July 2017
Efficacy and Safety of Tofacitinib Monotherapy...
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib...
26th June 2017
Outcomes of Tumor Necrosis Factor Inhibitor Cycling versus...
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor...
Biologics or Tofacitinib for People with Rheumatoid Arthritis Naïve to Methotrexate...
30th April 2017
EULAR RA Management Task Force, Ann Rheum Dis Published Online First: 06March2017. doi:10.1136/annrheumdis-2016-210715
Winthrop, Nature Reviews Rheumatology 2017;13:234–43
31st March 2017
20th October 2016
Prof. McInnes reviews the latest papers uploaded to the Cytokine Signalling Forum
15th September 2016
Prof. McInnes reviews the latest papers uploaded to the Cytokine Signalling Forum
26th July 2016
Prof. McInnes presents the CSF monthly podcast reviewing papers from Prof. Genovese and Prof. Takeuchi
View our CME Courses
25th February 2016
Prof. McInnes presents the CSF monthly podcast reviewing papers from Prof. J Zhang and Prof. Y Kaneko
20th January 2016
Prof. McInnes presents the CSF monthly podcast reviewing papers from Prof. Laure Gossec
22nd December 2015
Prof. McInnes presents the CSF monthly podcast reviewing papers from Prof. V Strand and Prof. C Gabay.
21st October 2015
Prof. Iain McInnes presents the inaugural monthly podcast reviewing papers by Prof. Wei Gao and Prof. Cem Gabay focusing on tofacitinib and tocilizumab respectively.
21st October 2015
Steering Committee chair Prof. Iain McInnes introduces his picks of the most important abstracts presented at ACR 2015.